Physician profile
James E Deweese
NPI 1578539987
$6,962.92
in general payments reported to CMS, 2019-2025
33 companies · $782 in 2025
The $782 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,327 · 2022: $1,046 · 2023: $2,261 · 2024: $1,547 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,431.74 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $654.34 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $463.79 | 2021-2024 | Mounjaro, Kisunla |
| Axsome Therapeutics, INC. | $333.33 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $331.27 | 2023-2024 | Voquezna |
| Esperion Therapeutics, INC. | $319.17 | 2021-2025 | Nexletol |
| Abbvie INC. | $295.18 | 2022-2025 | |
| Medtronic, INC. | $287.50 | 2024 | Endurant Iis |
| Otsuka America Pharmaceutical, INC. | $272.34 | 2022-2023 | Rexulti |
| Amgen INC. | $268.92 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $238.32 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.34 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.27 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $195.47 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $171.68 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $160.58 | 2021 | |
| Glaxosmithkline, LLC. | $149.52 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $142.70 | 2021-2023 | Veozah |
| Lundbeck LLC | $131.79 | 2023-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.17 | 2023 | |
| Alkermes, INC. | $115.71 | 2023 | Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $93.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $68.64 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $56.30 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.42 | 2021-2022 | |
| Exact Sciences Corporation | $46.99 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $44.55 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $19.75 | 2021 | |
| Seqirus USA INC | $15.16 | 2024 | Fluad, Flucelvax |
| Hologic Sales and Service, LLC | $14.70 | 2023 | Aptima, Thinprep 2000 Processor |
| Biohaven Pharmaceuticals, INC. | $13.50 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.42 | 2021 | |
| Daiichi Sankyo INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Deweese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.